AbbVie's (ABBV) Allergan Aesthetics Receives Health Canada Approval for Boey

AbbVie (ABBV) subsidiary Allergan Aesthetics announced on June 23, 2026, that Health Canada has approved Boey for the temporary improvement of moderate to severe glabellar lines in adults. This marks the first neurotoxin approval for this specific indication in Canada in over two decades. Boey, a purified botulinum toxin type A, targets the vertical lines that develop between the eyebrows. This approval expands Allergan Aesthetics' portfolio within the Canadian medical aesthetics market, offering a new treatment option for a common cosmetic concern.